These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2523156)

  • 21. Fine specificity of a panel of antibodies against the TCR/CD3 complex.
    Nashan B; Wonigeit K; Schwinzer R; Schlitt HJ; Kurrle R; Pichlmayr R
    Transplant Proc; 1987 Oct; 19(5):4270-2. PubMed ID: 2960057
    [No Abstract]   [Full Text] [Related]  

  • 22. Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3.
    Ellenhorn JD; Hirsch R; Hartley JP; Bluestone JA
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1013-4. PubMed ID: 2523110
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of neonatal injections of anti-CD3 epsilon monoclonal antibodies on the T cell functions of adult mice.
    Rueff-Juy D; Drapier AM; Cazenave PA
    J Immunol; 1989 Jun; 142(11):3788-95. PubMed ID: 2523935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose.
    Colonna JO; Millis JM; Martello J; Levy P; Iwaki Y; Brems JJ; Klein AS; Hiatt JR; Busuttil RW
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2247-8. PubMed ID: 2523600
    [No Abstract]   [Full Text] [Related]  

  • 25. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes.
    van Lier RA; Brouwer M; Rebel VI; van Noesel CJ; Aarden LA
    Immunology; 1989 Sep; 68(1):45-50. PubMed ID: 2530156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract]   [Full Text] [Related]  

  • 27. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

  • 28. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
    Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
    Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease cytokine production.
    Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
    Transplant Proc; 1993 Feb; 25(1 Pt 1):823-4. PubMed ID: 8094913
    [No Abstract]   [Full Text] [Related]  

  • 30. Monoclonal anti-CD44 antibody acts in synergy with anti-CD2 but inhibits anti-CD3 or T cell receptor-mediated signaling in murine T cell hybridomas.
    Guo YJ; Ma J; Wong JH; Lin SC; Chang HC; Bigby M; Sy MS
    Cell Immunol; 1993 Nov; 152(1):186-99. PubMed ID: 7694807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 32. Discordant expression of CD3 and T-cell receptor antigens on lymphocytes from patients treated with OKT3.
    Gebel HM; Lebeck LL; Jensik SC; Landay AL; Bray RA
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1745-6. PubMed ID: 2523590
    [No Abstract]   [Full Text] [Related]  

  • 33. Fine-needle aspiration cytology during treatment with orthoclone monoclonal antibody OKT3 for acute cellular rejection after renal transplantation.
    Hansen BL; Foged N; Nielsen E; Elbirk A; Rohr N; Svendsen V; Birkeland SA
    Transplant Proc; 1988 Aug; 20(4):626-8. PubMed ID: 2970142
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
    Chatenoud L; Ferran C; Legendre C; Kurrle R; Kreis H; Bach JF
    Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of the HLA-DRw6 antigen in liver transplantation.
    Saito S; Stratta RJ; Grazi GL; Castaldo P; Langnas AN; Wood RP; Shaw BW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1430-1. PubMed ID: 1824899
    [No Abstract]   [Full Text] [Related]  

  • 36. Adverse responses following intraoperative administration of orthoclone OKT3.
    Roth S; Kupferberg JP
    Anesth Analg; 1989 Dec; 69(6):822-5. PubMed ID: 2531559
    [No Abstract]   [Full Text] [Related]  

  • 37. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
    Li PK; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(3):123-55. PubMed ID: 1703724
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-TNF abrogates the cytokine-related anti-CD3 induced syndrome.
    Ferran C; Sheehan K; Schreiber R; Bach JF; Chatenoud L
    Transplant Proc; 1991 Feb; 23(1 Pt 1):849-50. PubMed ID: 1825003
    [No Abstract]   [Full Text] [Related]  

  • 40. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
    Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.